For The Earth Corporation (FTEG)

[pyro2]

Intentions of the government continue to appear positive, in establishing guidelines on CBD and Hemp in general, which is also a positive for FTEG, IMO.

FDA Commissioner Dr. Scott Gottleib provided testimony to the House Committee on Appropriations on the FDA’s status of operations. According to Gottleib, the FDA understands that “Congress wants there to be a pathway for CBD to be available.”

In his testimony on enforcement priorities, Gottlieb acknowledged that Congress intended to legalize industrial hemp and its derivatives via the 2018 Farm Bill. Time will tell if those propositions pay off, but they look pretty good right now — at least from an FDA enforcement perspective. Norman “Ned” Sharpless to be FDA acting Commissioner when Gottleib leaves this month.

Norman Sharpless will take over the top FDA post to be vacated by Scott Gottlieb, who also seemed generally friendly to (CBD) dietary supplements. Industry leaders expect little change from current views to move this forward quickly.